This was the stock's second consecutive day of losses.
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cybin (CYBN – Research Report) and Corbus ...
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price ...
4d
Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...
Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.
Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback